Profile data is unavailable for this security.
About the company
Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, scientific and other products. The Company operates through three business segments. The Endoscope segment provides gastrointestinal endoscopes, surgical endoscopes, and medical services. The Therapeutic Equipment segment provides gastrointestinal treatment instruments, urology products, respiratory products, energy devices, otolaryngology products and gynecology products. The Others segment provides biomaterials and orthopedic instruments. The Company is also engaged in the business activities, including holding companies and financial investments related to each business.
- Revenue in JPY (TTM)936.21bn
- Net income in JPY26.61bn
- Incorporated1919
- Employees28.84k
- LocationOlympus Corp2951, Ishikawa-machiHACHIOJI-SHI 192-8507JapanJPN
- Phone+81 426422111
- Fax+81 333402062
- Websitehttps://www.olympus.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 7733:TYO since announced | Transaction value |
|---|---|---|
| Olympus Terumo Biomaterials Corp | 18.06% | -- |
Data delayed at least 20 minutes, as of Jul 22 2024 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APT Medical Inc | 38.04bn | 12.38bn | 670.85bn | 2.16k | 54.24 | 14.95 | -- | 17.63 | 8.49 | 8.49 | 26.10 | 30.81 | 0.7036 | 1.51 | 45.45 | 814,768.60 | 22.49 | 18.12 | 28.32 | 21.94 | 70.36 | 70.30 | 31.96 | 27.07 | 2.71 | -- | 0.008 | 26.49 | 35.71 | 46.83 | 49.13 | 90.09 | 44.39 | -- |
| ASAHI INTECC CO., LTD. | 101.06bn | 15.16bn | 685.20bn | 10.19k | 45.19 | 4.73 | 27.65 | 6.78 | 55.82 | 55.82 | 372.06 | 533.45 | 0.5912 | 1.23 | 5.62 | 9,920,487.00 | 8.94 | 9.57 | 10.28 | 11.20 | 64.37 | 66.78 | 15.12 | 15.93 | 2.83 | 84.06 | 0.0543 | 28.13 | 15.89 | 12.44 | 20.71 | 5.47 | 9.12 | 8.31 |
| Pro Medicus Limited | 15.39bn | 7.34bn | 1.44tn | 79.00 | 196.82 | 86.19 | 175.54 | 93.83 | 0.6675 | 0.6675 | 1.40 | 1.52 | 0.7516 | 7.11 | 3.59 | -- | 35.84 | 29.98 | 40.92 | 35.44 | 99.71 | 99.18 | 47.68 | 44.89 | 7.49 | 48.30 | 0.0096 | 38.90 | 35.30 | 30.28 | 36.47 | 43.51 | 0.1966 | 37.97 |
| Sysmex Corp | 461.51bn | 49.64bn | 1.59tn | 10.04k | 31.86 | 3.64 | 18.56 | 3.44 | 79.26 | 79.26 | 736.61 | 692.94 | 0.8026 | 2.87 | 3.26 | 45,957,880.00 | 8.66 | 8.92 | 10.83 | 11.29 | 52.54 | 52.27 | 10.79 | 11.19 | 2.24 | 21.33 | 0.1141 | 39.12 | 12.43 | 9.47 | 8.42 | 3.79 | 11.61 | 3.71 |
| Fisher & Paykel Healthcare Corporatn Ltd | 164.96bn | 12.55bn | 1.73tn | 7.14k | 138.35 | 10.40 | 74.15 | 10.51 | 0.2266 | 0.2266 | 2.97 | 3.01 | 0.777 | 2.04 | 7.33 | 244,055.50 | 5.91 | 16.43 | 6.96 | 19.83 | 59.93 | 62.09 | 7.61 | 19.07 | 0.9987 | 18.03 | 0.0971 | 49.48 | 10.23 | 10.24 | -47.02 | -8.72 | 20.52 | 12.29 |
| Shanghai United Img Hlthcare Co Ltd | 250.21bn | 43.50bn | 1.98tn | 7.44k | 45.41 | 4.72 | -- | 7.90 | 2.44 | 2.44 | 14.01 | 23.46 | 0.4658 | 1.49 | 3.89 | 1,552,201.00 | 8.12 | -- | 10.50 | -- | 47.83 | -- | 17.44 | -- | 2.85 | -- | 0.0216 | -- | 23.52 | -- | 19.21 | -- | -- | -- |
| Cochlear Ltd | 226.25bn | 36.88bn | 2.30tn | 4.80k | 62.69 | 12.25 | 49.98 | 10.16 | 5.32 | 5.32 | 32.64 | 27.23 | 0.8602 | 1.74 | 5.14 | 447,791.70 | 14.02 | 8.91 | 17.45 | 11.69 | 75.46 | 74.97 | 16.30 | 12.19 | 1.94 | 175.39 | 0.104 | 90.63 | 17.46 | 7.26 | 3.98 | 3.58 | 14.05 | 1.92 |
| Olympus Corp | 936.21bn | 26.61bn | 3.20tn | 28.84k | 119.66 | 4.18 | 34.41 | 3.41 | 22.68 | 193.93 | 770.26 | 649.59 | 0.6153 | 1.76 | 5.03 | 32,464,460.00 | 1.77 | 6.38 | 2.51 | 9.06 | 66.77 | 65.88 | 2.88 | 9.91 | 1.41 | 10.62 | 0.2835 | 21.73 | 6.16 | 3.35 | -80.69 | 26.71 | 1.01 | 19.14 |
| Terumo Corp | 921.86bn | 106.37bn | 4.14tn | 30.59k | 38.90 | 3.11 | 22.63 | 4.50 | 71.47 | 71.47 | 619.37 | 893.80 | 0.537 | 1.64 | 5.87 | 30,135,070.00 | 6.20 | 6.25 | 7.50 | 7.37 | 52.18 | 52.50 | 11.54 | 12.11 | 1.15 | -- | 0.1683 | 29.37 | 12.39 | 8.99 | 19.09 | 6.01 | 7.70 | 10.26 |
Data as of Jul 22 2024. Currency figures normalised to Olympus Corp's reporting currency: Japanese Yen JPY
36.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 28 Apr 2023 | 82.91m | 7.04% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 65.60m | 5.57% |
| Capital Research & Management Co. (World Investors)as of 14 Jul 2023 | 61.57m | 5.23% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 38.20m | 3.24% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 37.55m | 3.19% |
| BlackRock Fund Advisorsas of 31 Oct 2022 | 36.93m | 3.14% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 34.47m | 2.93% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 30.37m | 2.58% |
| BlackRock Japan Co. Ltd.as of 31 Oct 2022 | 26.96m | 2.29% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 11 Sep 2023 | 20.10m | 1.71% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
